pravastatin has been researched along with fluorobenzenes in 109 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 64 (58.72) | 29.6817 |
| 2010's | 45 (41.28) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stein, EA | 2 |
| Fahmy, M; Mahla, G; Mizan, J; Paoletti, R; Southworth, H | 1 |
| Hasegawa, H; Higaki, K; Inazawa, K; Koike, M; Matsumura, T; Nakano, M; Nezasa, K | 1 |
| Bays, HE; Brown, WV; Chitra, R; Hassman, DR; Hutchinson, H; McKenney, J; Miller, E | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Higaki, K; Koike, M; Nakano, M; Nezasa, K; Takeuchi, M | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Edwards, JE; Moore, RA | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| D'Haese, PC; De Broe, ME; Verhulst, A | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Rosenson, RS | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Bulhak, AA; Gonon, AT; Gourine, AV; Pernow, J; Sjöquist, PO; Valen, G | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Carbonell, T; Freire, E | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Davidson, M | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Izar, MC | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Kawasaki, A; Kesler, A; Purvin, V; Smith, KH | 1 |
| Einecke, D | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kagawa, T; Kobayashi, M; Takano, R | 1 |
| Imai, S; Kitamura, A; Komuro, S; Yabuki, M | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Cannon, CP; Kumar, A | 1 |
| Desamericq, G; Kieffer, A; Laforest, L; Le Jeunne, P; Moulin, P; Ritleng, C; Schwalm, MS; Souchet, T; Van Ganse, E | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Doggrell, SA | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Ford, JS; Tayek, JA | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Higuchi, S; Ieiri, I | 1 |
| Chan, ES; Mak, KH | 1 |
| Backman, JT; Keskitalo, JE; Kurkinen, KJ; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Endo, C; Kitamura, S; Kusuhara, H; Miyajima, M; Ose, A; Sugiyama, Y; Tohyama, K | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Boccara, F; Bonnefont-Rousselot, D; Costagliola, D; Fiévet, MH; Giral, P; Kalmykova, O; Melchior, JC; Peytavin, G; Valantin, MA | 1 |
| Hata, M; Hirayama, A; Minami, K; Sezai, A; Takayama, T; Yoshitake, I | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Baker, WL; Coleman, CI; Talati, R; White, CM | 1 |
| Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y | 1 |
| Daida, H; Hata, M; Kaku, K; Kawamori, R; Kishimoto, J; Kurabayashi, M; Masuda, I; Nohara, R; Sakuma, I; Yamazaki, T; Yokoi, H; Yoshida, M | 4 |
| Abt, M; Bech, N; Derks, M; Meneses-Lorente, G; Parr, G; Phelan, M; Turnbull, L; White, AM | 1 |
| Daitoku, K; Fukuda, I; Hanada, H; Higuma, T; Okumura, K; Osanai, T; Saito, S; Yokoyama, H | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Coleman, T; Howe, K; Plant, N; Sanat, F; Thumser, AE | 1 |
| Bi, YA; Gong, LK; Hiramatsu, M; Kotani, N; Kusuhara, H; Maeda, K; Sugiyama, Y; Takezawa, T; Watanabe, T | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Abe-Dohmae, S; Fitzgerald, ML; Iwamoto, N; Tanaka, N; Yokoyama, S | 1 |
| Arai, H; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| D'Haese, P; Geryl, H; Verhulst, A | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Ishibashi, Y; Matsui, T; Nakamura, K; Ohta, K; Okuda, S; Takeuchi, M; Tanoue, R; Ueda, S; Yamagishi, S | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Galetin, A; Houston, JB; Kenworthy, KE; Ménochet, K | 1 |
| Aslangul, E; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Barton, HA; El-Kattan, AF; Goosen, TC; Gosset, JR; Jones, HM; Lai, Y; Lin, J; Varma, MV | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Ikeda, T; Ikuta, S; Iwanaga, Y; Kobuke, K; Miyazaki, S; Ueno, M; Yamaji, K; Yamamoto, H; Yasuda, M | 1 |
| Ara, N; Iuchi, A; Miyoshi, H; Mizuguchi, Y; Nagase, N; Oishi, Y; Oki, T | 1 |
| Uemura, S | 1 |
| Chen, L; Chu, X; Dallas, S; Evers, R; Geier, EG; Kehler, J; Kunta, J; Laplanche, L; Mamaril-Fishman, D; Mezler, M; Pang, J; Prasad, B; Rode, A; Salphati, L; Scheer, N; Schinkel, AH; Soars, MG; Unadkat, JD; van Waterschoot, RA; Yabut, J | 1 |
| Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Bailey, DG; Dixon, S; Fleet, JL; Gandhi, S; Garg, AX; Gomes, T; Juurlink, D; Kim, R; Li, DQ; Mamdani, M; McArthur, E; Shariff, SZ | 1 |
23 review(s) available for pravastatin and fluorobenzenes
| Article | Year |
|---|---|
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Statins: can the new generation make an impression?
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Statin-associated myasthenia gravis: report of 4 cases and review of the literature.
Topics: Aged; Autoantibodies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myasthenia Gravis; Pravastatin; Pyrimidines; Receptors, Cholinergic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs].
Topics: Fluorobenzenes; Haplotypes; Humans; Liver-Specific Organic Anion Transporter 1; Metformin; Octamer Transcription Factor-1; Organic Anion Transporters; Pharmacogenetics; Pharmacokinetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Racial Groups; Rosuvastatin Calcium; Sulfonamides | 2009 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.
Topics: Anticholesteremic Agents; Blood Glucose; Blood Pressure; Body Size; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Patient Selection; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.
Topics: Cell Line; Chemical Phenomena; Drug Evaluation, Preclinical; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Kinetics; Liver; Membrane Transport Proteins; Models, Theoretical; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
33 trial(s) available for pravastatin and fluorobenzenes
| Article | Year |
|---|---|
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study.
Topics: Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2001 |
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy.
Topics: Aged; Anticholesteremic Agents; Cardiovascular System; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2010 |
Can intensive lipid-lowering therapy with statins ameliorate atherosclerosis in Japanese patients? Rationale and design of the JART study.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Japan; Male; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Tunica Intima; Tunica Media; Young Adult | 2010 |
Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Topics: Adult; Amides; Anticholesteremic Agents; Area Under Curve; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Esters; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfhydryl Compounds; Sulfonamides | 2010 |
Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease.
Topics: Adiponectin; Aged; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heart Valve Diseases; Humans; Interleukin-6; Intra-Abdominal Fat; Male; Middle Aged; Oxidative Stress; Pravastatin; Protein Carbonylation; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Tumor Necrosis Factor-alpha | 2011 |
No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis.
Topics: Adult; Aged; Albuminuria; Cross-Over Studies; Double-Blind Method; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proteinuria; Proteome; Proteomics; Pyrimidines; Retinol-Binding Proteins; Rosuvastatin Calcium; Sulfonamides; Two-Dimensional Difference Gel Electrophoresis | 2011 |
Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Topics: Aged; Asian People; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Hypolipidemic Agents; Japan; Longitudinal Studies; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.
Topics: Female; Fluorobenzenes; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides | 2013 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; France; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Japan; Lipid Metabolism; Male; Middle Aged; Outcome Assessment, Health Care; Pharmacovigilance; Pravastatin; Preventive Health Services; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Neointima; Percutaneous Coronary Intervention; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2014 |
Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Influence of comorbid cardiovascular risk factors on left atrial-left ventricular interaction in asymptomatic patients: clinical application of two-dimensional speckle-tracking echocardiography.
Topics: Aged; Atherosclerosis; Atrial Function, Left; Carotid Intima-Media Thickness; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
56 other study(ies) available for pravastatin and fluorobenzenes
| Article | Year |
|---|---|
Are some statins more equal than others.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2002 |
Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.
Topics: Algorithms; Animals; Anticholesteremic Agents; Area Under Curve; Autoradiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Liver; Male; Pravastatin; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Silver Staining; Simvastatin; Sulfonamides; Tissue Distribution | 2002 |
Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin.
Topics: Algorithms; Animals; Anion Transport Proteins; Anticholesteremic Agents; Antimetabolites; Binding, Competitive; Diffusion; Fluorobenzenes; Hepatocytes; Kinetics; Male; Pravastatin; Proteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2003 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells.
Topics: Cells, Cultured; Endocytosis; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Receptors, Cell Surface; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level.
Topics: Administration, Oral; Animals; Blood Pressure; Cholesterol; Female; Fluorobenzenes; Heart; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peroxidase; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Swine | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
[Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy].
Topics: Cyclosporine; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Effect of medium pH on the cytotoxicity of hydrophilic statins.
Topics: Animals; Apoptosis; Caspases; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Fluorobenzenes; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Skeletal; Myoblasts; Pravastatin; Pyrimidines; Rats; Rhabdomyosarcoma, Embryonal; Rosuvastatin Calcium; Sulfonamides; Tetrazolium Salts; Thiazoles; Toxicity Tests | 2007 |
The new acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems.
Topics: Binding, Competitive; Biological Transport, Active; Cryopreservation; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Estrone; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver-Specific Organic Anion Transporter 1; Naphthyridines; Oocytes; Organic Anion Transporters; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Genotype; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Capillaries; Cell Line; Cell Membrane; Cerebral Cortex; Choroid Plexus; Digoxin; Enkephalin, D-Penicillamine (2,5)-; Fluorobenzenes; Gene Expression; Humans; Ion Pumps; Kinetics; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Ochratoxins; Organic Anion Transporters; Organic Cation Transport Proteins; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Quinolines; Recombinant Proteins; Rosuvastatin Calcium; Sulfonamides; Taurocholic Acid; Tetrahydroisoquinolines; Transfection | 2010 |
Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
Topics: Anticholesteremic Agents; Coronary Artery Bypass; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrimidines; Radiography; Rosuvastatin Calcium; Saphenous Vein; Sulfonamides; Ultrasonography; Vascular Diseases | 2009 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Topics: Cell Line, Tumor; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Fluorobenzenes; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pravastatin; Pregnane X Receptor; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes.
Topics: Animals; Bile; Biological Transport; Cell Culture Techniques; Cells, Cultured; Digoxin; Fluorobenzenes; Hepatocytes; Humans; Inactivation, Metabolic; Liver; Male; Membrane Transport Proteins; Pravastatin; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides; Taurocholic Acid | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jurkat Cells; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Phagocytosis; Pravastatin; Pyrimidines; RNA Interference; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Transfection; Up-Regulation | 2011 |
Differential effect of statins on diabetic nephropathy in db/db mice.
Topics: Adiposity; Albuminuria; Animals; Blood Pressure; Body Weight; Creatinine; Diabetic Nephropathies; Fluorobenzenes; Insulin Resistance; Male; Mice; Oxidative Stress; Pravastatin; Pyrimidines; Quinolines; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
Topics: Amidohydrolases; Apoptosis; Arginine; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fluorobenzenes; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Pravastatin; Pyrimidines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2012 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Transport; Bosentan; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kinetics; Models, Biological; Organic Anion Transporters; Piperidines; Pravastatin; Pyrimidines; Quinolines; Rats; Rosuvastatin Calcium; Species Specificity; Sulfonamides; Telmisartan; Tetrazoles; Valine; Valsartan | 2012 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
Statins and prevention of stent-related late adverse events.
Topics: Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neointima; Percutaneous Coronary Intervention; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Topics: Animals; Drug Interactions; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2014 |
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperkalemia; Indoles; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pravastatin; Pyrimidines; Retrospective Studies; Rhabdomyolysis; Rosuvastatin Calcium; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides | 2015 |